Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06976697 · ClinicalTrials.gov registry record · NA

Home-Based tDCS Treatment Of Major Depressive Disorder

A NA study of Major Depressive Disorder (MDD), sponsored by Sooma Medical.

Recruiting
Registry status
NA
Development phase
200
Enrollment target
1
Study location

NCT06976697 is a NA study of Major Depressive Disorder (MDD) that is actively recruiting participants, run by Sooma Medical. The registered enrollment target is 200 participants, above the 149-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (34% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06976697, a NA study of Major Depressive Disorder (MDD), is actively recruiting participants, sponsored by Sooma Medical.

RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
1
Study location

Study Summary

The REACH-tDCS study will evaluate the safety and efficacy of a noninvasive, at-home self-administered Sooma tDCS brain stimulation treatment for Major Depressive Disorder. The study uses randomized, blinded, placebo controlled design. The participants are assessed with video interviews and self-reports during the study, which lasts for 10 weeks followed by an optional continuation period.

Interventions

  • DEVICE Sham transcranial direct current stimulation
  • DEVICE Transcranial direct current stimulation

Study Locations (1)

Massachusetts

  • Lindus Health (virtual study site) - Boston

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2025-06-27
Est. Completion 2026-12-23
Phase NA

Sponsor

Sooma Medical

1 total trials

What the Registry Record Tells You About NCT06976697

The ClinicalTrials.gov registry entry for NCT06976697 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 149-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target (34% higher). The listed sponsor is Sooma Medical, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 2 interventions - of which Sham transcranial direct current stimulation is the first listed.

NCT06976697 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06976697 about?

NCT06976697 is a clinical study titled "Home-Based tDCS Treatment Of Major Depressive Disorder". The REACH-tDCS study will evaluate the safety and efficacy of a noninvasive, at-home self-administered Sooma tDCS brain stimulation treatment for Major Depressive Disorder. The study uses randomized, blinded, placebo controlled design. The participants are assessed with video interviews and self-rep...

What is the current status of trial NCT06976697?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2025-06-27. Estimated completion is 2026-12-23.

What conditions does trial NCT06976697 study?

This clinical trial studies the following conditions: Major Depressive Disorder (MDD).

What interventions are being tested in trial NCT06976697?

The interventions under investigation include: Sham transcranial direct current stimulation (DEVICE), Transcranial direct current stimulation (DEVICE).

Who is sponsoring clinical trial NCT06976697?

This trial is sponsored by Sooma Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06976697 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Major Depressive Disorder (MDD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.